Provided by Tiger Fintech (Singapore) Pte. Ltd.

ArTara Therapeutics, Inc.

4.32
+0.21005.11%
Post-market: 4.400.0800+1.85%19:36 EDT
Volume:440.73K
Turnover:1.90M
Market Cap:158.84M
PE:-1.99
High:4.50
Open:4.19
Low:4.10
Close:4.11
Loading ...

Sector Update: Health Care Stocks Decline Thursday Afternoon

MT Newswires Live
·
06 Dec 2024

Top Midday Gainers

MT Newswires Live
·
06 Dec 2024

Protara Therapeutics Shares More Than Double After Co Reports Mid-Stage Data for Bladder Cancer Therapy

THOMSON REUTERS
·
05 Dec 2024

Protara Says Phase 2 Bladder Cancer Trial Shows 72% Complete Response Rate at 6 Months

MT Newswires Live
·
05 Dec 2024

Wall Street Set to Open Flat Thursday; Initial Jobless Claims Higher Than Expected

MT Newswires Live
·
05 Dec 2024

Protara Therapeutics Shares Soar on Positive Data for Bladder Cancer Treatment Trials

Dow Jones
·
05 Dec 2024

Investors Await Jobless Claims Data as Markets Tread Water in Thursday's Premarket

MT Newswires Live
·
05 Dec 2024

Protara Therapeutics Shares up 48.9% Premarket After Co Reports Mid-Stage Data for Bladder Cancer Therapy

THOMSON REUTERS
·
05 Dec 2024

BUZZ-Protara Therapeutics gains on mid-stage data on bladder cancer therapy

Reuters
·
05 Dec 2024

BRIEF-Protara Announces Positive Results From The Ongoing Phase 2 Advanced-2 Trial Of TARA-002 In Patients With NMIBC

Reuters
·
05 Dec 2024

Protara Announces Positive Results From the Ongoing Phase 2 Advanced-2 Trial of Tara-002 in Patients With Nmibc

THOMSON REUTERS
·
05 Dec 2024

Protara Therapeutics Inc: in Tara-002, Favorable Safety & Tolerability Profile With No Grade 2 or Greater Treatment-Related Adverse Events

THOMSON REUTERS
·
05 Dec 2024

Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

GlobeNewswire
·
05 Dec 2024

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024

GlobeNewswire
·
03 Dec 2024

Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Simply Wall St.
·
22 Nov 2024

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

GlobeNewswire
·
16 Nov 2024